Vaishali Pharma launches series of immunity booster products worldwide

Apurva Joshi
/ Categories: Trending, Mindshare, DSIJ News
Vaishali Pharma launches series of immunity booster products worldwide

Vaishali Pharma Limited has successfully launched its series of immunity booster products worldwide. The products range includes Vipravita C (tablets and effervescent), Vipravita CZ (tablets), Vipravita D3, Viprafolic A, Vipravita, Vipramultivita, Ascorzee (tablet), herbal cough drops, Viprasure (powder), Vipra C (Gummies), Vipra B (Gummies), Vipra M (Gummies), multi-vitamin (effervescent), Women D (effervescent). 

These products would help to improve immunity and fight against disease-causing germs like bacteria, COVID -19 viruses, parasites or fungi, etc. 

It has launched these products across countries like Sudan, Oman, Dubai, Iraq, Congo, Kenya, Sri Lanka, Philippines, Lesotho, etc. 

This has enabled the company to strengthen its presence in the high growth market and reach out to more and more territories. Last month, it had received an order worth USD 2,70,000 from Afghanistan for the supply of API, packaging material like capsule, glass vial, rubber stopper, flip-off seal, sterile water for injection, etc, and specific machinery setup such as tablets manufacturing machines. 

Vaishali Pharma is amongst the leading players in the supply of pharma products – bulk drugs/APIs, formulations, surgical products, veterinary supplements, herbal & nutraceutical products. It has over 150+ formulation brands marketed in multiple countries and also, built a robust pipeline of around 250 dossiers. 

On Monday, the stock of Vaishali Pharma opened at Rs 42.30 on NSE. At 11.28 am, it was trading 3.10 per cent up at Rs 43.20 from its previous close of Rs 41.90. 

Rate this article:
5.0

Leave a comment

Add comment

DSIJ MINDSHARE

Mkt Commentary29-Apr, 2024

Mindshare29-Apr, 2024

Multibaggers29-Apr, 2024

Penny Stocks29-Apr, 2024

Bonus and Spilt Shares29-Apr, 2024

Knowledge

General26-Apr, 2024

Fundamental21-Apr, 2024

General21-Apr, 2024

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR